Jul 14, 2025
Dr. Abe Delpassand, Founder, CEO, and Chairman of the Board at RadioMedix, is concentrated on the development of radiopharmaceuticals for cancer diagnosis and treatment. Advancements in handling radioactive materials and increased availability have enabled the growth of the use of alpha-emitting and beta-emitting radioisotopes in treating cancers that have been resistant to other therapies. Alpha-emitting radioisotopes are particularly interesting because they can cause double-strand DNA damage in cancer cells, making the probability of cancer recurrence much less likely.
Abe explains, "Just a brief introduction related to what radiopharmaceuticals are. These are drugs that have three parts, basically. One part is the radioactive material. The second part is what we call a ligand. It's like a vehicle that takes the radioactive material to the target that we have. And there is a third component, which is like a chain attaching the radioisotope to the ligand. Radiopharmaceuticals qualify as a form of therapy because we target a specific receptor antigen metabolic pathway in cancer cells, and this is how we can reach the cancer cells. It has two components: one, diagnostic and therapeutic, which is very unique to this modality because in many other cancer therapies before the treatment, we don't have any way to make sure that the patient who is receiving the treatment, that actually the drug can reach the cancer the patient has."
"We have been talking about the value of alpha-emitters in delivering high level of radiation in a targeted fashion to the cancer cells, but we in the last, I'd say 10 years or more, we have learned how to handle these isotopes. That's one aspect of the science part. The other aspect is the availability of these isotopes. Now the supply of these isotopes is becoming a lot more, and they are becoming more available."
#RadioMedix #TeamRadioMedix #Radiopharmaceuticals #TargetedAlphaTherapy #OncologyInnovation #NuclearMedicine #CancerResearch #RadiogandTherapy #PrecisionOncology #Theranostics #SPICACenter #OncologyCommunity #AlphaEmittingRadioisotopes #BetaEmittingRadioisotopes
